Welcome to CDC stacks | Economic impact of antimicrobial resistance. - 15101 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Economic impact of antimicrobial resistance.
  • Published Date:
    2001 Mar-Apr
  • Source:
    Emerg Infect Dis. 7(2):286-292.
Filetype[PDF-66.32 KB]


Details:
No Related Documents.
You May Also Like:
  1. A public health perspective on antimicrobial resistance diagnostics : meeting summary and opportunities to address challenges
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); AdvaMedDx.;
    Published:
    March 2016
    Description:
    On December 4, 2015, CDC’s Division of Healthcare Quality Promotion’s Office of Antimicrobial Resistance (OAR) and AdvaMedDx hosted an all-day meeting with industry leaders to forecast the future development of diagnostic tests and look for solut...
    File Type:
    Filetype[PDF - 412.36 KB]
  2. Reference Group Choice and Antibiotic Resistance Outcomes
    Personal Author:
    Kaye, Keith S.; Engemann, John J.; Mozaffari, Essy; Carmeli, Yehuda;
    Published:
    Jun 2004
    Source:
    Emerg Infect Dis. 10(6):1125-1128.
    Description:
    Two types of cohort studies examining patients infected with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) were contrasted, using different reference groups. Cases were compared to uninfected patients a...
    File Type:
    Filetype[PDF - 71.45 KB]
  3. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery.
    Personal Author:
    Zanetti, G.; Goldie, S. J.; Platt, R.;
    Published:
    2001 Sep-Oct
    Source:
    Emerg Infect Dis. 7(5):820-827.
    Description:
    Routine us of vancomycin for perioperative prophylaxis is discouraged, principally to minimize microbial resistance to it. However, outcomes and costs of this recommendation have not been assessed. We used decision-analytic models to compare clinical...
    File Type:
    Filetype[PDF - 75.90 KB]
  4. A Public health action plan to combat antimicrobial resistance; Domestic issues; Part 1
    Corporate Author:
    United States, Interagency Task Force on Antimicrobial Resistance.
    Published:
    2001
    Description:
    The Interagency Task Force on Antimicrobial Resistance is co-chaired by the Centers for Disease Control and Prevention, Food and Drug Administration, and the National Institutes of Health. It also includes the Agency for Healthcare Research and Quali...
    File Type:
    Filetype[PDF - 114.23 KB]
  5. Controversies in the prevention and control of antimicrobial drug resistance.
    Personal Author:
    Bell, D.
    Published:
    1998 Jul-Sep
    Source:
    Emerg Infect Dis. 4(3):473-474.
    File Type:
    Filetype[PDF - 203.59 KB]